Individualized cost-effectiveness analysis

John P A Ioannidis, Alan M Garber, John P A Ioannidis, Alan M Garber

Abstract

John Ioannidis and Alan Garber discuss how to use incremental cost-effectiveness ratios (ICER) and related metrics so they can be useful for decision-making at the individual level, whether used by clinicians or individual patients.

Conflict of interest statement

JI is a member of the PLoS Medicine Editorial Board. The authors have declared that no other competing interests exist.

References

    1. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
    1. Willan AR. On the probability of cost-effectiveness using data from randomized clinical trials. BMC Med Res Methodol. 2001;1:8.
    1. O'Hagan A, Stevens JW. The probability of cost-effectiveness. BMC Med Res Methodol. 2002;2:5.
    1. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661–687.
    1. McLaughlin MJ HTE Policy Roundtable Panel. Healthcare policy implications of heterogeneity of treatment effects. Am J Med. 2007;120(4) Suppl 1:S32–S35.
    1. Greenfield S, Kravitz R, Duan N, Kaplan SH. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med. 2007;120(4) Suppl 1:S3–S9.
    1. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ. 1995;311:1356–1359.
    1. Garber AM. Advances in cost-effectiveness analysis of health interventions. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics, Volume 1. Amsterdam: North-Holland; 2000. pp. 181–221.
    1. Mendeloff J, Ko K, Roberts MS, Byrne M, Dew MA. Procuring organ donors as a health investment: how much should we be willing to spend? Transplanation. 2004;78:1704–1710.
    1. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–332.
    1. Luce R. Utility of gains and losses: measurement-theoretical and experimental approaches. Mahwah (New Jersey): Lawrence Erlbaum Associates; 2000.
    1. Byrnes JP, Miller DC, Schafer WD. Gender differences in risk taking: A meta-analysis. Psych Bull. 1999;125:367–383.
    1. Elbasha EH. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach. Health Econ. 2005;14:457–470.
    1. Sapienza P, Zingales L, Maestripieri D. Gender differences in financial risk aversion and career choices are affected by testosterone. Proc Natl Acad Sci U S A. 2009;106:15268–15273.
    1. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med. 2009;151:612–621.
    1. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73–83.
    1. Pletcher MJ, Lazar L, Bibbins-domingo K, Moran A, Rodondi N, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid lowering. Ann Intern Med. 2009;150:243–254.
    1. Paulden M, Palmer S, Hewitt C, Gilbody S. Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ. 2009;339:b5203. doi: .
    1. Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009;339:b2538. doi: .
    1. Epstein D, Bojke L, Sculpher MJ REFLUX Trial Group. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. BMJ. 2009;339:b2576. doi: .
    1. Rose J, Hawthorn RL, Watts B, Singer ME. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ. 2009;339:b3653. doi: .
    1. Barton GR, Sach TH, Jenkinson C, Doherty M, Avery AJ, et al. Lifestyle interventions for knee pain in overweight and obese adults aged > or = 45: economic evaluation of randomised controlled trial. BMJ. 2009;339:b2273.
    1. Laska EM, Meisner M, Siegel C. Statistical inference for cost-effectiveness ratios. Health Econ. 1997;6:229–242.
    1. Briggs A, Fenn P. Trying to do better than average: a commentary on ‘statistical inference for cost-effectiveness ratios’. Health Econ. 1997;6:491–495.
    1. Ioannidis JP, Lau J. The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol. 1997;50:1089–1098.
    1. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
    1. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418–1424.
    1. Gilbody S, Wilson P, Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Qual Saf Health Care. 2005;14:246–250.
    1. Wright CF, Hall A, Zimmern RL. Regulating direct-to-consumer genetic tests: What is all the fuss about? Genet Med. 2011;13:295–300.
    1. Cohen JP, Paquette C, Cairns CP. Switching prescription drugs to over the counter. BMJ. 2005;330:39–41.
    1. Nease RF, Jr, Owens DK. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making. 1994;14:382–392.
    1. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke. 1998;29:1083–1091.
    1. Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs (healthy-years equivalent) versus QALYs (quality-adjusted live-year). J Health Econ. 1993;12:325–339.
    1. Mehrez A, Gafni A. Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making. 1989;9:142–149.
    1. Mehrez A, Gafni A. The healthy-years equivalents: how to measure them using the standard gamble approach. 1991;11:140–146.
    1. Hutchings A, Durand MA, Grieve R, Harrison D, Rowan K, et al. Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis. BMJ. 2009;339:b4353. doi: .
    1. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884. doi: .
    1. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009;151:829–839.
    1. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006;332:699–703.
    1. Miners AH, Garau M, Fidan D, Fischer AJ. Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study. BMJ. 2005;330:65.
    1. Polyzos NP, Valachis A, Mauri D, Ioannidis JPA. Sponsorship bias in assumptions of cost-effectiveness analysis: the diagnostic accuracy of the Pap test. CMAJ. 2011 In press.
    1. Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics. 2007;25:807–816.
    1. O'Brien BJ, Sculpher MJ. Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules. Med Care. 2000;38:460–468.
    1. Owens DK, Qaseem A, Chou R, Shekelle P Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154:174–180.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir